文献速递肝肾功能剂量调整药物相互作用

达比加群酯、达比加群及其葡萄糖醛酸结合物的全身生理药代动力学模型:健康成人与肾功能不全患者

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

本研究构建了涵盖达比加群酯、达比加群及达比加群1-O-酰基葡萄糖醛酸结合物的全身PBPK模型,利用13项研究数据(剂量0.1-300 mg,静脉/口服,胶囊/溶液)及利福平、克拉霉素相互作用研究进行开发与验证。模型预测的AUC、谷浓度和半衰期均满足两倍误差接受标准;在严重肾功能不全中,将UGT2B15代谢和P-gp转运速率分别降至健康成人的67%和65%后,模型能准确预测肾功能不全患者的药代动力学。

要点

  • PBPK模型可区分达比加群酯、活性成分达比加群及主要活性代谢物葡萄糖醛酸结合物。
  • 严重肾功能不全时需将UGT2B15代谢和P-gp转运速率分别下调至健康成人的67%和65%。
  • 模型预测的AUC、谷浓度和半衰期均满足两倍误差接受标准。

核心结论

  • 首次实现可区分达比加群酯、达比加群及主要活性代谢物的PBPK模型。
  • 调整UGT2B15代谢和P-gp转运速率后,模型能准确预测肾功能不全患者的药代动力学。

研究设计与样本

  • 基于理化性质与ADME参数、13项健康及肾功能不全研究(剂量0.1-300 mg,静脉/口服,胶囊/溶液)及利福平、克拉霉素相互作用研究进行模型开发与评估。

主要发现

  • 预测的AUC、谷浓度和半衰期值满足两倍误差接受标准。
  • 达比加群酯和达比加群的代谢清除基于羧酸酯酶1/2和UGT2B15数据实现。
  • 严重肾功能不全时,模型中将UGT2B15代谢和P-gp转运速率分别降至健康成人的67%和65%。

关键数值与推荐

  • 模型接受标准为预测值与观测值的比值在2倍以内。

临床怎么用

  • 该模型可用于机制性评估肾功能不全对达比加群药代动力学的影响。
  • 模型整合了P-gp诱导(利福平)和抑制(克拉霉素)的相互作用数据,支持药物相互作用评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The thrombin inhibitor dabigatran is administered as the prodrug dabigatran etexilate, which is a substrate of esterases and P-glycoprotein (P-gp). Dabigatran is eliminated via renal excretion but is also a substrate of uridine 5'-diphospho (UDP)-glucuronosyltransferases (UGTs). The objective of this study was to build a physiologically based pharmacokinetic (PBPK) model comprising dabigatran etexilate, dabigatran, and dabigatran 1-O-acylglucuronide to describe the pharmacokinetics in healthy adults and renally impaired patients mechanistically. METHODS: Model development and evaluation were carried out using (i) physicochemical and absorption, distribution, metabolism, and excretion (ADME) parameter values of all three analytes; (ii) concentration-time profiles from 13 studies of healthy and renally impaired individuals after varying doses (0.1-300 mg), intravenous (dabigatran) and oral (dabigatran etexilate) administration, and different formulations of dabigatran etexilate (capsule, solution); and (iii) drug-drug interaction studies of dabigatran with the P-gp perpetrators rifampin (inducer) and clarithromycin (inhibitor). RESULTS: A PBPK model of dabigatran was successfully developed. The predicted area under the plasma concentration-time curve, trough concentration, and half-life values of the assessed clinical studies satisfied the two-fold acceptance criterion. Metabolic clearances of dabigatran etexilate and dabigatran were implemented using data on carboxylesterase 1/2 enzymes and UGT subtype 2B15. In severe renal impairment, the UGT2B15 metabolism and the P-gp transport in the model were reduced to 67% and 65% of the rates in healthy adults. CONCLUSION: This is the first implementation of a PBPK model for dabigatran to distinguish between the prodrug, active moiety, and main active metabolite. Following adjustment of the UGT2B15 metabolism and P-gp transport rates, the PBPK model accurately predicts the pharmacokinetics in renally impaired patients.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Moj D, Maas H, Schaeftlein A, et al. A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients. Clin Pharmacokinet. 2019. PMID: 31104266. doi:10.1007/s40262-019-00776-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。